FR2418794A1 - Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant - Google Patents

Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant

Info

Publication number
FR2418794A1
FR2418794A1 FR7904573A FR7904573A FR2418794A1 FR 2418794 A1 FR2418794 A1 FR 2418794A1 FR 7904573 A FR7904573 A FR 7904573A FR 7904573 A FR7904573 A FR 7904573A FR 2418794 A1 FR2418794 A1 FR 2418794A1
Authority
FR
France
Prior art keywords
prostaglandin
analogues
pharmaceutical compositions
compositions containing
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7904573A
Other languages
English (en)
Other versions
FR2418794B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of FR2418794A1 publication Critical patent/FR2418794A1/fr
Application granted granted Critical
Publication of FR2418794B1 publication Critical patent/FR2418794B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

L'invention concerne de nouveaux analogues de la prostaglandine I2 . Ces composés ont la formule ci-dessous, dans laquelle Y = éthylène ou vinylène trans, R**1 = H, alcoyle, aralcoyle, cycloalcoyle substitué ou non, phényle substitué ou non, alcoxycarbonylalcoyle, hydroxy- ou alcoxyalcoyle, ou dialcoylaminoalcoyle, R**2 = H, méthyle ou éthyle, X = alcoylène, cyclo-alcoylène ou combinaison des deux, et R**3 = Cl ou F. Applications pharmacologiques, plus particulièrement dans le domaine cardio-vasculaire.
FR7904573A 1978-03-01 1979-02-22 Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant Granted FR2418794A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2215078A JPS54115368A (en) 1978-03-01 1978-03-01 Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent

Publications (2)

Publication Number Publication Date
FR2418794A1 true FR2418794A1 (fr) 1979-09-28
FR2418794B1 FR2418794B1 (fr) 1981-11-27

Family

ID=12074820

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7904573A Granted FR2418794A1 (fr) 1978-03-01 1979-02-22 Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant

Country Status (7)

Country Link
US (1) US4232009A (fr)
JP (1) JPS54115368A (fr)
CH (1) CH638196A5 (fr)
DE (1) DE2906699A1 (fr)
FR (1) FR2418794A1 (fr)
GB (1) GB2016007B (fr)
IT (1) IT1113401B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401139A2 (fr) * 1977-03-07 1979-03-23 Upjohn Co Nouveaux derives d5 de prostaglandines, leur procede de preparation et medicaments les contenant

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
DE2902809A1 (de) * 1979-01-25 1980-08-07 Hoechst Ag Neue analoga von prostacyclin
HU184949B (en) * 1981-04-14 1984-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 4-oxo-pgi down 2 and analogues thereof
US4623641A (en) 1985-09-09 1986-11-18 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5942501A (en) * 1996-08-16 1999-08-24 Collaborative Laboratories, Inc. Cyclodextrin derivative complex
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2401139A2 (fr) * 1977-03-07 1979-03-23 Upjohn Co Nouveaux derives d5 de prostaglandines, leur procede de preparation et medicaments les contenant
FR2401141A1 (fr) * 1977-03-07 1979-03-23 Upjohn Co Nouveaux derives halogenes de prostaglandines et medicaments les contenant

Also Published As

Publication number Publication date
GB2016007B (en) 1982-11-24
CH638196A5 (fr) 1983-09-15
IT1113401B (it) 1986-01-20
US4232009A (en) 1980-11-04
JPS6148510B2 (fr) 1986-10-24
GB2016007A (en) 1979-09-19
JPS54115368A (en) 1979-09-07
IT7920596A0 (it) 1979-02-27
FR2418794B1 (fr) 1981-11-27
DE2906699A1 (de) 1979-09-06

Similar Documents

Publication Publication Date Title
FR2422635A1 (fr) Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant
FR2418794A1 (fr) Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant
FR2356424A1 (fr) Compositions pharmaceutiques a base d'acide phophono-formique utiles pour lutter contre les infections virales
BE1002211A4 (fr) (pentamethyl-1,2,2,6,6 piperidyl-4-amino)-triazines, leur application comme stabilisants de matieres organiques, et compositions qui en contiennent.
FR2403333A1 (fr) Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant
FR2416234A1 (fr) Derives de metronidazole et compositions pharmaceutiques en contenant
FR2383171A1 (fr) Derives de thiopropanoylaminoacides utiles comme hypotenseurs
FR2369297A1 (fr) Nouveaux esters d'acides androstadiene-17-carboxyliques
FR2374307A1 (fr) Derives de la 1,4-dihydropyridine, leur procede d'obtention et composition pharmaceutique les contenant
FR2404005A1 (fr) Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant
FR2381043A1 (fr) Nouveaux analogues de prostaglandines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2442844A1 (fr) Analogues de la prostaglandine i1 et compositions pharmaceutiques les contenant
DK607783A (da) Nitroaliphatiske forbindelser
KR860700250A (ko) 신규 아미딘 화합물
FR2415636A1 (fr) Nouveaux derives de la guanidine, leur preparation et leur application comme medicaments
FR2419935A1 (fr) Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant
FR2378777A1 (fr) Nouveaux analogues de prostaglandines
FR2447375A1 (fr) Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant
NZ182556A (en) Tricylick azacyloalkanones
FR2370745A1 (fr) Nouveaux derives de la morphanthridine, leur preparation et leur application comme medicaments
BE1003436A3 (fr) Derives cycliques et leurs metabolites, leur preparation et leur utilisation comme medicaments.
RU93004472A (ru) Полициклические биоцидные соединения и композиция на их основе
FR2400520A1 (fr) Nouveaux derives du phosphore utilisables comme stabilisants de matieres organiques et leur preparation
FR2403347A1 (fr) Nouveaux derives du phosphore utilisables comme stabilisants de matieres organiques et leur preparation
FR2404637A1 (fr) Analogues de prostaglandines et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
ST Notification of lapse